Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$2.73 - $5.57 $117,117 - $238,953
42,900 Added 56.45%
118,900 $344,000
Q4 2024

Feb 14, 2025

BUY
$4.08 - $5.96 $310,080 - $452,960
76,000 New
76,000 $362,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $385M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Omers Administration Corp Portfolio

Follow Omers Administration Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Omers Administration Corp, based on Form 13F filings with the SEC.

News

Stay updated on Omers Administration Corp with notifications on news.